Cipla Ltd.

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating closure of the inspection at API manufacturing facility in Bommasandra, Bangalore. The agency had conducted inspection from January 20, 2020 to January 24, 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.